Status:

COMPLETED

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

Lead Sponsor:

National University of Malaysia

Conditions:

PreDiabetes

Type 2 Diabetes

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the therapeutic r...

Detailed Description

A 12-week, open-label, single treatment study using linagliptin is conducted in 28 prediabetes and 22 T2DM subjects who are divided into low and high fasting GLP-1 groups. Prediabetes are recruited fr...

Eligibility Criteria

Inclusion

  • Prediabetes diagnosed from OGTT and T2DM subjects
  • HbA1c \> 6.5% and \<10%
  • Subjects not receiving any glucose-lowering medication or just receiving metformin and/or sulphonylureas and/or alpha-glucosidase inhibitors on stable dose for at least 3 months.
  • Subjects who are willing to participate and sign the informed consent form

Exclusion

  • Subjects with ketoacidosis or lactic acidosis, overt diabetes, another disease causing secondary glucose intolerance, congestive heart failure (New York Heart Association Class III or IV), myocardial infarction, stroke or ischemic attacks in past 6 months, uncontrolled severe hypertension, active liver conditions such as cirrhosis or hepatitis \[elevation in liver enzymes to higher activities than double the respective normal value\], moderate to severe renal insufficiency, pregnancy, breast-feeding
  • Patients receiving insulin, GLP-1 receptor agonists, dipeptidyl peptidase IV inhibitors or glucose-lowering medications other than metformin /sulphonylureas /alpha-glucosidase inhibitors as treatment.
  • Subjects with uncontrolled blood glucose HbA1c\>10%
  • Subjects who plan to move out of state / country

Key Trial Info

Start Date :

August 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT05290506

Start Date

August 1 2020

End Date

March 1 2021

Last Update

March 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Sultan Ismail

Johor Bahru, Johor, Malaysia, 81100

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus | DecenTrialz